BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 24838471)

  • 21. Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
    Ravaioli M; Lai Q; Sessa M; Ghinolfi D; Fallani G; Patrono D; Di Sandro S; Avolio A; Odaldi F; Bronzoni J; Tandoi F; De Carlis R; Pascale MM; Mennini G; Germinario G; Rossi M; Agnes S; De Carlis L; Cescon M; Romagnoli R; De Simone P
    J Hepatol; 2022 Mar; 76(3):619-627. PubMed ID: 34774638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
    Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
    Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil.
    Pestana RC; Baracat EI; Massarollo PC; Pereira LA; Szutan LA
    Transplant Proc; 2013; 45(6):2111-4. PubMed ID: 23747144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
    Berry K; Ioannou GN
    Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
    Toso C; Dupuis-Lozeron E; Majno P; Berney T; Kneteman NM; Perneger T; Morel P; Mentha G; Combescure C
    Hepatology; 2012 Jul; 56(1):149-56. PubMed ID: 22271250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes utilizing imported liver grafts for recipients with hepatocellular carcinoma.
    Battula N; Reichman TW; Amiri Y; Carmody IC; Galliano G; Seal J; Bugeaud E; Bohorquez H; Bruce D; Cohen A; Loss GE
    Liver Transpl; 2017 Mar; 23(3):299-304. PubMed ID: 28026108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
    Goldberg D; French B; Abt P; Feng S; Cameron AM
    Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis.
    Lee MW; Raman SS; Asvadi NH; Siripongsakun S; Hicks RM; Chen J; Worakitsitisatorn A; McWilliams J; Tong MJ; Finn RS; Agopian VG; Busuttil RW; Lu DSK
    Hepatology; 2017 Jun; 65(6):1979-1990. PubMed ID: 28170115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Effect of Bridging Locoregional Therapy and Sociodemographics on Survival in Hepatocellular Carcinoma Patients Undergoing Orthotopic Liver Transplantation: A United Network for Organ Sharing Population Study.
    Magnetta MJ; Xing M; Zhang D; Kim HS
    J Vasc Interv Radiol; 2016 Dec; 27(12):1822-1828. PubMed ID: 27692856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma.
    Samuel D; Colombo M; El-Serag H; Sobesky R; Heaton N
    Liver Transpl; 2011 Oct; 17 Suppl 2():S6-13. PubMed ID: 21858912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significant Reduction in Posttransplant Hepatocellular Carcinoma Recurrence in the Post 6-Mo Waiting Policy Era.
    Mahmud N; Yagan L; Hoteit MA; Reddy KR; Abt PL; Abu-Gazala S
    Transplantation; 2024 May; 108(5):1172-1178. PubMed ID: 37953481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Racial Disparities in Candidates for Hepatocellular Carcinoma Liver Transplant After 6-Month Wait Policy Change.
    Saberi B; Gurakar A; Tamim H; Schneider CV; Sims OT; Bonder A; Fricker Z; Alqahtani SA
    JAMA Netw Open; 2023 Nov; 6(11):e2341096. PubMed ID: 37917059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Racial-ethnic differences in liver transplant waitlist outcomes in patients with hepatocellular carcinoma before and after recent changes to allocation policy.
    Mazur RD; Cron DC; Goldberg DS; Yeh H; Dageforde LA
    Clin Transplant; 2024 Jun; 38(6):e15365. PubMed ID: 38804605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
    Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection.
    Seshadri RM; Besur S; Niemeyer DJ; Templin M; McKillop IH; Swan RZ; Martinie JB; Russo MW; Iannitti DA
    HPB (Oxford); 2014 Dec; 16(12):1102-9. PubMed ID: 24964271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum sodium and survival benefit of liver transplantation.
    Sharma P; Schaubel DE; Goodrich NP; Merion RM
    Liver Transpl; 2015 Mar; 21(3):308-13. PubMed ID: 25504743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form.
    Mehta N; Dodge JL; Roberts JP; Hirose R; Yao FY
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28881064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation.
    Goldaracena N; Gorgen A; Doyle A; Hansen BE; Tomiyama K; Zhang W; Ghanekar A; Lilly L; Cattral M; Galvin Z; Selzner M; Bhat M; Selzner N; McGilvray I; Greig PD; Grant DR; Sapisochin G
    J Hepatol; 2019 Apr; 70(4):666-673. PubMed ID: 30630009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation.
    Schmitz S; Lurje G; Ulmer F; Andert A; Bruners P; Schulze-Hagen M; Neumann U; Schoening W
    Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):228-236. PubMed ID: 30718181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.